دورية أكاديمية

Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus:A bedside-to-bench approach

التفاصيل البيبلوغرافية
العنوان: Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus:A bedside-to-bench approach
المؤلفون: Mikkelsen, Rasmus R, Hundahl, Malthe P, Torp, Christopher K, Rodríguez-Carrio, Javier, Kjolby, Mads, Bruun, Jens M, Kragstrup, Tue W
المصدر: Mikkelsen , R R , Hundahl , M P , Torp , C K , Rodríguez-Carrio , J , Kjolby , M , Bruun , J M & Kragstrup , T W 2022 , ' Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus : A bedside-to-bench approach ' , European Journal of Pharmacology , vol. 925 , 174998 . https://doi.org/10.1016/j.ejphar.2022.174998Test
سنة النشر: 2022
المجموعة: Aarhus University: Research
مصطلحات موضوعية: Animals, Cardiovascular Diseases/drug therapy, Colchicine, Diabetes Mellitus, Type 2/complications, Etanercept/pharmacology, Humans, Hydroxychloroquine/therapeutic use, Immunosuppression Therapy, Inflammation/chemically induced, Interleukin 1 Receptor Antagonist Protein/therapeutic use, Methotrexate/therapeutic use, Sulfasalazine/therapeutic use, Hydroxychloroquine/pharmacology, Immunomodulating Agents/pharmacology, Sulfasalazine/pharmacology, Colchicine/pharmacology, Interleukin-1/antagonists & inhibitors, Type 2/drug therapy, Interleukin 1 Receptor Antagonist Protein/pharmacology, Interleukin-1beta/antagonists & inhibitors, Antibodies, Monoclonal, Humanized/pharmacology, Immunosuppressive Agents/pharmacology, Inflammation/drug therapy, Methotrexate/pharmacology
الوصف: OBJECTIVE: To assess which immunosuppressive drugs have been investigated and proven efficacious in patients with cardiovascular disease (CVD) or type 2 diabetes (T2D) without preexisting immune mediated disorders to validate in vitro and animal model findings on low grade inflammation (bedside-to-bench). METHODS: Clinical trials on immunosuppressive drugs in CVD or T2D were found in PubMed. Studies on patients with preexisting immune mediated inflammatory disease were excluded. A total of 19 clinical trials testing canakinumab, anakinra, methotrexate, colchicine, hydroxychloroquine, etanercept and sulfasalazine were found. RESULTS: Canakinumab and colchicine significantly reduced the risk of CVD, whereas methotrexate did not. Sulfasalazine showed no effect on vascular function. Anakinra and hydroxychloroquine had a positive effect on glycemic control and β-cell function in T2D. Etanercept had no effect in patients with T2D. CONCLUSION: The observed results indicate that immunosuppressive drugs specifically targeting IL-1β hold promise for dampening CVD and T2D. These findings validate in vitro and animal models showing involvement of the IL-1-axis in the pathogenesis of CVD and T2D. The use of immunosuppressive drugs targeting the chronic inflammation in these diseases could be a possible future treatment strategy as an add-on to the existing pharmacological treatment of CVD and T2D. However, potential treatment effects, adverse events and cost-effectiveness should be carefully considered with importance for drug development.
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: https://pure.au.dk/portal/da/publications/immunomodulatory-and-immunosuppressive-therapies-in-cardiovascular-disease-and-type-2-diabetes-mellitusTest(89dc7ad3-f029-46e6-b0e6-b29b06deb44c).html
DOI: 10.1016/j.ejphar.2022.174998
الإتاحة: https://doi.org/10.1016/j.ejphar.2022.174998Test
https://pure.au.dk/portal/da/publications/immunomodulatory-and-immunosuppressive-therapies-in-cardiovascular-disease-and-type-2-diabetes-mellitusTest(89dc7ad3-f029-46e6-b0e6-b29b06deb44c).html
https://pure.au.dk/ws/files/352590179/1-s2.0-S001429992200259X-main.pdfTest
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.5F474101
قاعدة البيانات: BASE